EUROPE ANTI-RHEUMATICS MARKET FORECAST 2020-2028

EUROPE ANTI-RHEUMATICS MARKET FORECAST 2020-2028

  • April 2020 •
  • 115 pages •
  • Report ID: 5880963 •
  • Format: PDF
KEY FINDINGS
The Europe anti-rheumatics market is predicted to reach a CAGR of 2.10% over the forecast period of 2020-2028. A huge patient base of rheumatoid arthritis, owing to a large geriatric population, is one of the crucial factors favoring the market growth in the region.

MARKET INSIGHTS
The Europe anti-rheumatics market is researched further by segmenting the region into countries such as France, Russia, the UK, Poland, Germany, Belgium, Italy, and the rest of Europe that comprises of Greece, Austria, Netherland, Switzerland, Spain, Ireland, among others. In Russia, the prevalence of RA is estimated at 0.61% and has remained stable over the years. RA has been associated with many humanistic outcomes in spite of its low prevalence. Rheumatic disease is the second most common pathology after cardiovascular disorders, with 10% of the population being affected by RD. The most common RDs are osteoarthritis, rheumatoid arthritis, gout, and low back pain. The major factors responsible for the rising prevalence of RDs are hypertension, obesity, diabetes mellitus, and others. In countries like Belgium, the RA deaths accounted for 0.07% of the total deaths. Currently, around 80,000 to 100,000 people have this medical condition in Belgium. Since there is no known cure for RA, physicians focus on suppressing the disease. Therapies have improved in recent years, and intensive treatment in the early stages of RA can prevent joint damage and improve quality of life. The rapid improvement in therapy is driving the market.
In Poland, the most widely used DMARDs is methotrexate, which, in accordance with EULAR recommendations, is administered in RA treatment.Moreover, the program for the treatment of GPA and MPA was introduced, thereby promoting the market growth.

The prevalence of RA, together with the increasing healthcare facilities, are propelling the market growth in the rest of Europe.

COMPETITIVE INSIGHTS
F. Hoffmann-La Roche Ltd, Abbott Laboratories, Novartis International AG, UCB, Becton, Dickinson, and Company, etc. are some of the renowned companies functioning in the market.

Companies mentioned
1. ABBOTT LABORATORIES
2. ABBVIE INC
3. AMGEN INC
4. BECTON, DICKINSON & COMPANY (BD)
5. BIO-RAD LABORATORIES INC
6. BRISTOL-MYERS SQUIBB COMPANY
7. ELI LILLY & COMPANY
8. LUPIN LIMITED
9. F. HOFFMANN-LA ROCHE
10. JOHNSON & JOHNSON
11. MERCK & CO INC
12. NOVARTIS AG
13. PERKINELMER
14. PFIZER INC
15. UCB